- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S1221
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase |
|---|---|
| Other Antineoplastic and Immunosuppressive Antibiotics Inhibitors | Staurosporine (STS) Cyclosporin A Puromycin Dihydrochloride Oligomycin A (MCH 32) Geldanamycin Honokiol Streptozotocin (STZ) Cephalomannine Sodium Monensin (NSC 343257) 10-Deacetylbaccatin-III |
|
In vitro |
DMSO
: 3 mg/mL
(16.46 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 182.18 | Formula | C6H10N6O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 4342-03-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | DTIC-Dome, Imidazole Carboxamide,NSC-45388 | Smiles | CN(C)N=NC1=C(NC=N1)C(=O)N | ||
| Targets/IC50/Ki |
Nucleoside antimetabolite/analog
|
|---|---|
| In vitro |
Treatment of Dacarbazine sensitizes melanomas to lysis of peptide-specific CTL and it is mediated through Fas-independent pathway.
|
| In vivo |
Treatment of combination of Axitinib and this compound demonstrates significant antitumor activity against melanoma flank xenografts, reduces tumor cell proliferation and decreases the area of tumor necrosis and increases apoptosis. It also reduces meta-tasis-related factors and prolongs lifespan in mice.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | ATM / p-ATM / p21(Waf1/Cip1) / Survivin |
|
27632933 |
| Growth inhibition assay | Cell viability |
|
21976975 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03761095 | Completed | Leiomyosarcoma |
PTC Therapeutics |
March 13 2019 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
Could you please help me test some common vehicles for it in vivo experiments?
Answer:
It can dissolve in 0.5% CMC Na at 30mg/ml as a suspension. After staying for a period of time, the powder will drop down to the bottom of the tube, so please vortex well before use.